Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
The purpose of this study is to use Chemo-radio-immunotherapy and maintenance therapy with Nivolumab and Ipilimumab in order to achieve improved outcome in patients with locally advanced cervical cancer.
Cervical Cancer â‰¥ FIGO IIB and or Lymph Node Metastases
DRUG: Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|DRUG: Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|PROCEDURE: Maintenance Treatment (Nivolumab/Ipilimumab)
Progression free survival (PFS), Tumor response assessed by MRI Pelvic according to resist, From Baseline to 2 years|The adverse events according to NCI-CTCAE v5.0, Safety and tolerability (according to NCI-CTCAE v5.0), From the time of signed informed consent until 100 days after the last study drug administration
After being informed about the study and potential risks, all eligible patients giving written informed consent will undergo a Pre-Chemo-radio-immunotherapy Treatment with Nivolumab and Ipilimumab for 2 weeks. In the following week 1-7, concurrent Chemo-radio-Immunotherapy will consist of standard administration of concurrent Cisplatin mono during radiotherapy, with simultaneous application of Nivolumab and Ipilimumab according to trial protocol. This is followed by Maintenance Treatment for 6 months with Nivolumab and Ipilimumab according to trial protocol.